OncoXome
Developer of an engineered plant-derived exosome delivery platform designed for targeted oral delivery of molecular oncology therapies. The platform is described as isolating and engineering plant-derived extracellular vesicles, loading them with nucleic acid payloads (CRISPR-Cas9, siRNA, mRNA and other nucleic acids), and delivering those payloads orally to tumor cells. The site reports preclinical in vivo demonstrations of tumor targeting, tumor reduction in colorectal cancer models, and no observed toxicity at tested doses. Headquarters listed in Los Angeles, California, USA.
Industries
Nr. of Employees
small (1-50)
Products
Engineered plant-derived exosome delivery platform
A platform that isolates, engineers, and loads plant-derived exosomes with therapeutic payloads for oral delivery to tumor cells; described payloads include CRISPR-Cas9, siRNA, and mRNA and reported to have demonstrated in vivo targeting and tumor reduction.
Engineered Plant-Derived Exosomes
Biocompatible, targeted, oral delivery, and scalable exosome delivery system derived from plants, designed for targeted tumor delivery with high loading capacity and versatile payload options.
Engineered plant-derived exosome delivery platform
A platform that isolates, engineers, and loads plant-derived exosomes with therapeutic payloads for oral delivery to tumor cells; described payloads include CRISPR-Cas9, siRNA, and mRNA and reported to have demonstrated in vivo targeting and tumor reduction.
Engineered Plant-Derived Exosomes
Biocompatible, targeted, oral delivery, and scalable exosome delivery system derived from plants, designed for targeted tumor delivery with high loading capacity and versatile payload options.
Expertise Areas
- Exosome engineering and delivery
- Oral drug delivery
- Nucleic acid therapeutic delivery (CRISPR-Cas9, siRNA, mRNA)
- Preclinical in vivo validation
Key Technologies
- Plant-derived exosomes (extracellular vesicles)
- Exosome isolation and characterization
- Exosome engineering and payload loading
- Nucleic acid delivery (CRISPR-Cas9, siRNA, mRNA)
News & Updates
Site reports that engineered plant-derived exosomes delivered mRNA, siRNA, and CRISPR-Cas9 to colorectal tumor cells in vivo, resulting in tumor reduction and control; no toxicity was reported at tested doses.
Site reports that engineered plant-derived exosomes delivered mRNA, siRNA, and CRISPR-Cas9 to colorectal tumor cells in vivo, resulting in tumor reduction and control; no toxicity was reported at tested doses.